e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

38.27 +0.56 (+1.49%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about NewAmsterdam Pharma Company N.V. - Ordinary Shares

< Previous 1 2 3 Next >

Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗

November 20, 2025

Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗

November 20, 2025

Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Gets Booted in Latest Fund Update ↗

November 19, 2025

Bain Capital sold its entire stake in Nuvalent stock during the third quarter.

Via The Motley Fool

Topics Regulatory Compliance

7 Analysts Have This To Say About NewAmsterdam Pharma ↗

February 27, 2025

Via Benzinga

Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings) ↗

January 24, 2025

Via Benzinga

Where NewAmsterdam Pharma Stands With Analysts ↗

December 30, 2024

Via Benzinga

Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma ↗

December 05, 2024

Via Benzinga

Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗

November 19, 2025

Bain Capital completely exited its position in Disc Medicine stock during the third quarter

Via The Motley Fool

Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗

November 18, 2025

Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.

Via The Motley Fool

Topics Regulatory Compliance

Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings) ↗

October 20, 2025

Via Benzinga

Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts ↗

August 25, 2025

Via Benzinga

What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co ↗

August 07, 2025

Via Benzinga

NewAmsterdam (NAMS) Q2 Revenue Jumps 49% ↗

August 06, 2025

Via The Motley Fool

What Analysts Are Saying About NewAmsterdam Pharma Co Stock ↗

June 12, 2025

Via Benzinga

Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib ↗

June 09, 2025

NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.

Via Benzinga

Get insights into the top gainers and losers of Monday's pre-market session. ↗

June 09, 2025

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 22, 2025

Via Benzinga

The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts ↗

April 08, 2025

Via Benzinga

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? ↗

March 31, 2025

The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.

Via Investor's Business Daily

Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

February 26, 2025

Via Benzinga

Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗

February 26, 2025

Via Benzinga

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

January 16, 2025

Via Benzinga

Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio? ↗

December 15, 2024

These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN.

Via Benzinga

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating ↗

December 11, 2024

NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.

Via Investor's Business Daily

Top 3 Health Care Stocks That May Collapse This Quarter ↗

December 11, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 10, 2024

Via Benzinga

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? ↗

December 10, 2024

NewAmsterdam Pharma reports Phase 3 trial success for obicetrapib, achieving significant LDL-C reduction in ASCVD and HeFH patients on standard therapy.

Via Benzinga

United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday ↗

December 10, 2024

Via Benzinga

NewAmsterdam Pharma Soars 41% On An Surprise Benefit From Cholesterol Drug ↗

December 10, 2024

The results bode well for an ongoing Phase 3 study examining cardiovascular outcomes.

Via Investor's Business Daily

NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study ↗

November 20, 2024

The company's combination treatment lowered LDL cholesterol by about 50% over 84 days.

Via Investor's Business Daily

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy